A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies

Mitsune Tanimoto, Ryuzo Ohno, Yukio Kato, Junki Takamatsu, Eiji Watanabe, Hisamitsu Suzuki, Yasuo Morishtma, Htdeo Takeyama, Masahide Kobayashi, Kanji Ogata, Yoshthisa Kodera, Kohji Ezaki, Kohet Kawashtma, Tadasht Kamtya, Saburo Minami, Haruya Yoshtkawa, Hiroshi Nishiwaki, Satoshi Yoshikawa, Kazumasa Yamada

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

N4-Behenoy1-1-β-D-arabinofuranosy1cytosine (BH-AC) was administered to 11 patients with acute leukemia and five patients with other malignancies in a Phase I and TI clinical trial. Among 16 patients, 14 received BH-AC after being refractory to prior therapies, and two with acute leukemia received BH-AC for their first remission induction therapy.The starting dose was 1.5mg/kg administered as a single i.v. infusion of three hours. The doses were then escalated up to 5.0 mg/kg. No side effects were noted with single i.v. infusions. Daily consecutive infusions of 2.0 mg to 6.0 mg/kg for four to 21 days resulted in two patients experiencing nausea, two anorexia and one developing skin eruptions. Significant hematological effects were noted by the daily infusions. One patient with acute myeloblastic leukemia achieved complete remission with 5.0 mg/kg BH-AC administered daily for 21 days.BH-AC is active in acute leukemia and may play a role in the combination regimens for this disease.

Original languageEnglish
Pages (from-to)153-160
Number of pages8
JournalJapanese journal of clinical oncology
Volume8
Issue number2
Publication statusPublished - Dec 1978

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies'. Together they form a unique fingerprint.

Cite this